Developed skills and lines of research
Antonio Recchiuti is researcher in clinical pathology at the Department of Medical, Oral, and Biotechnological Sciences (DSMOB) at the University “G. d’Annunzio” in Chieti–Pescara.
He earned a degree in Pharmaceutical Chemistry and Technology in 2003 and a PhD in 2007 at the same university. From 2007 to 2010, he worked as a postdoctoral researcher in Charles Serhan’s laboratory at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA), where he initiated his research into the mechanisms of inflammation resolution. In 2011, he received the Marie Curie Career Integration Grant.
In 2014, he began his collaboration with FFC Ricerca as a Principal Investigator, leading a project aimed at studying potential treatments for chronic inflammation and infection in cystic fibrosis, allowing him to lead his first research group. He has been the leader and external collaborator of four other projects funded by FFC Ricerca.
He coordinates the Laboratory for Experimental and Clinical Pathology of Resolution at the Center for Advanced Studies and Technology (CAST). His primary research interests include studying the biomolecular and pharmacological actions of specialized pro-resolving lipid mediators (SPMs), which regulate the inflammatory response and its resolution.
Projects funded by FFC Ricerca as Principal Investigator or as Research Manager
FFC#13/2024
Unraveling proresolving effects of CFTR modulators on lung inflammation and infection
FFC#20/2021
Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic
FFC#19/2020
Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic
FFC#19/2016
Resolvin D1 for targeting chronic lung inflammation, infection, and damage in cystic fibrosis
FFC#21/2014
Resolvin D1 for Targeting Chronic Lung Inflammation and Infection in Cystic Fibrosis
Publications from FFC Research projects
Codagnone, M Cianci E, Lamolinara A et al. Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Mucosal Immunol. 2018 Jan;11(1):35-49. doi: 10.1038/mi.2017.36. Epub 2017 Apr 19.
Loretta Ferrera, Debora Baroni, Oscar Moran. Lumacaftor-rescued F508del-CFTR Has a Modified Bicarbonate Permeability. J Cyst Fibrosis, 18 (5), 602-605 Sep 2019
Antonio Recchiuti, Domenico Mattoscio, Elisa Isopi. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Front Pharmacol, 10, 252 2019 Apr 2 eCollection 2019.
Antonio Recchiuti, Veronica Cecilia Mari, Elisa Isopi, Domenico Mattoscio, Alessia Lamolinara, Marco D’Aurora, Valentina Gatta, Manuela Iezzi, Alessandra Bragonzi, Paolo Moretti, Marc Dubordeau, Marilina Codagnone, Eleonora Cianci, Mario Romano. Pro-resolutive actions of Resolvin D1 in cystic fibrosis. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14 (Suppl 1):5